Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Suspended 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 2Uterine Neoplasms 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Cancer 1

Interventions

pembrolizumab 8Paclitaxel 8Carboplatin 6niraparib 3Megestrol Acetate 3Cisplatin 3tislelizumab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2rucaparib 2olaparib 2iso-sulfan blue 2copanlisib 2Taxes 2Surveys and Questionnaires 2Nivolumab 2Lymph Node Excision 2Indocyanine Green 2Fulvestrant 2Filgrastim 2Doxorubicin 2Docetaxel 2tremelimumab 1spartalizumab 1sonidegib 1ribociclib 1rebastinib 1pemigatinib 1nicotinamide-beta-riboside 1lenvatinib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Neoplasms × gedatolisib × Clear all
NCT01420081 2019-01-08

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Pfizer

Phase 2 Terminated
67 enrolled 37 charts
Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡